Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Research leads way for noninvasive detection of early stage liver cancer

Research leads way for noninvasive detection of early stage liver cancer

Researchers explore how low-level electrical stimulation reduces inflammation

Researchers explore how low-level electrical stimulation reduces inflammation

Denali launched to discover, develop effective medicines for neurodegenerative diseases

Denali launched to discover, develop effective medicines for neurodegenerative diseases

New work challenges long-held beliefs about link between hippocampus and improved memory function

New work challenges long-held beliefs about link between hippocampus and improved memory function

Eating Mediterranean diet helps delay cognitive decline

Eating Mediterranean diet helps delay cognitive decline

Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries may accelerate aging process, increase dementia risk

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

Discovery paves way for developing treatments for people addicted to cocaine, amphetamines

β-amyloid deposition highly variable in synucleinopathy

β-amyloid deposition highly variable in synucleinopathy

Knowing the physical structure of amyloid beta-42 offers new view on amyloid propagation in Alzheimer's

Knowing the physical structure of amyloid beta-42 offers new view on amyloid propagation in Alzheimer's

GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

GTEx findings reveal how genomic variants can affect gene activity and disease susceptibility

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

NIH-sponsored Phase 1 clinical trial evaluates novel investigational West Nile virus vaccine

New epilepsy drug holds promise as Alzheimer's treatment

New epilepsy drug holds promise as Alzheimer's treatment

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Ground-breaking study characterizes early-stage Alzheimer's abnormalities in the intact brain

Ground-breaking study characterizes early-stage Alzheimer's abnormalities in the intact brain

Proteomics helps identify previously unrecognized proteins and pathways in nerve regeneration

Proteomics helps identify previously unrecognized proteins and pathways in nerve regeneration

Researchers uncover new connection between Alzheimer's disease and diabetes

Researchers uncover new connection between Alzheimer's disease and diabetes

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

Predominant first Alzheimer’s symptoms vary with diagnosis age

Predominant first Alzheimer’s symptoms vary with diagnosis age

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

New study finds that challenging work tasks may have significant effect on brain health

New study finds that challenging work tasks may have significant effect on brain health

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.